Barclays Issues Positive Forecast for Humana (NYSE:HUM) Stock Price

Humana (NYSE:HUM) had its price target hoisted by investment analysts at Barclays from $582.00 to $587.00 in a report issued on Monday, Benzinga reports. The firm currently has an “overweight” rating on the insurance provider’s stock. Barclays‘s price objective would suggest a potential upside of 35.35% from the company’s previous close.

A number of other equities analysts have also recently commented on HUM. Cantor Fitzgerald lifted their target price on Humana from $460.00 to $495.00 and gave the company an “overweight” rating in a research report on Monday. Wells Fargo & Company raised Humana from an “equal weight” rating to an “overweight” rating and boosted their price target for the company from $227.00 to $502.00 in a report on Monday, July 13th. JPMorgan Chase & Co. upped their price target on Humana from $316.00 to $393.00 and gave the stock a “neutral” rating in a research report on Monday, August 10th. Monness Crespi & Hardt raised Humana to a “buy” rating in a research note on Friday, October 9th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and set a $420.00 price objective on shares of Humana in a research report on Friday. Twenty-one research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $462.87.

Humana Stock Performance

HUM stock traded down $0.05 during midday trading on Monday, reaching $433.69. 637,112 shares of the company’s stock traded hands, compared to its average volume of 1,637,193. The company has a current ratio of 1.65, a quick ratio of 1.74 and a debt-to-equity ratio of 0.61. Humana has a 52-week low of $163.11 and a 52-week high of $456.50. The stock has a market cap of $52.08 billion, a P/E ratio of 42.32, a PEG ratio of 2.67 and a beta of 0.65. The stock’s 50-day moving average is $403.96 and its 200 day moving average is $312.27.

Humana (NYSE:HUM) last issued its quarterly earnings results on Friday, November 6th. The insurance provider reported ($0.70) earnings per share for the quarter, topping the consensus estimate of ($1.00) by $0.30. Humana had a net margin of 0.81% and a return on equity of 8.50%. The business had revenue of $41.16 billion for the quarter, compared to analysts’ expectations of $40.87 billion. During the same quarter last year, the company posted $3.24 EPS. The company’s revenue was up 26.1% compared to the same quarter last year. Humana has set its FY 2026 guidance at 9.500- EPS. As a group, analysts anticipate that Humana will post 9.03 EPS for the current year.

Institutional Investors Weigh In On Humana

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Diversified Trust Co grew its position in shares of Humana by 23.2% during the third quarter. Diversified Trust Co now owns 4,041 shares of the insurance provider’s stock worth $1,542,000 after purchasing an additional 760 shares in the last quarter. Moors & Cabot Inc. raised its stake in Humana by 4.3% during the 3rd quarter. Moors & Cabot Inc. now owns 804 shares of the insurance provider’s stock valued at $307,000 after purchasing an additional 33 shares during the period. Allworth Financial LP raised its stake in Humana by 51.1% during the 3rd quarter. Allworth Financial LP now owns 2,658 shares of the insurance provider’s stock valued at $1,056,000 after purchasing an additional 899 shares during the period. Russell Investments Group Ltd. lifted its holdings in Humana by 9.2% in the 3rd quarter. Russell Investments Group Ltd. now owns 413,336 shares of the insurance provider’s stock worth $158,101,000 after purchasing an additional 34,831 shares in the last quarter. Finally, Eurizon Capital SGR S.p.A. lifted its holdings in Humana by 1.5% in the 3rd quarter. Eurizon Capital SGR S.p.A. now owns 21,164 shares of the insurance provider’s stock worth $8,078,000 after purchasing an additional 303 shares in the last quarter. 92.38% of the stock is owned by institutional investors.

Humana Company Profile

Humana Inc is a U.S. health and wellness company that provides health insurance and healthcare services. Its insurance offerings include Medicare Advantage, Medicare Supplement and prescription drug plans, as well as Medicaid and employer-sponsored plans.

The company also provides care through CenterWell, its healthcare services brand, which includes primary care, home health and pharmacy services. Its insurance and care offerings are available in markets across the United States, with availability varying by product and location.

Humana was founded in 1961 as a nursing home company and later expanded into health insurance.